C
Context Therapeutics Inc. (CNTX)
NCM – Real vaqt narxi. Valyuta: USD
2.48
+0.09 (3.77%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
2.48
+0.09 (3.77%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Context Therapeutics Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, qattiq o'smalarni davolash uchun mahsulotlarni ishlab chiqadi. Kompaniyaning mahsulot nomzodi CLDN6 x CD3 bispesifik antitelasi bo'lgan CTIM-76 ni o'z ichiga oladi, u CLDN6 ni ifoda etadigan yomon sifatli hujayralarga T-hujayralar vositasida lizisni yo'naltirishga mo'ljallangan. Kompaniya Integral Molecular, Inc. bilan saraton terapiyasi uchun CLDN6 bispesifik monoklonal antitelani ishlab chiqish bo'yicha hamkorlik va litsenziyalash shartnomasiga ega. Kompaniya 2015 yilda tashkil etilgan va Filadelfiya, Pensilvaniya shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Karen Chagin M.D. | Chief Medical Officer |
| Mr. Alex C. Levit Esq., J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. Christopher Beck M.B.A. | Senior Vice President of Operations |
| Mr. Jeffrey Liebman | Associate Director of Accounting |
| Mr. Martin A. Lehr | Co-Founder, President, CEO & Director |
| Ms. Jennifer Dashnau M.B.A., Ph.D. | Senior Vice President of Technical Operations |
| Ms. Jennifer Minai-Azary | CFO & Treasurer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 10-Q | cntx-20260331.htm |
| 2026-05-01 | 8-K | cntx-20260430.htm |
| 2026-04-28 | DEFA14A | contexttherapeutics2026pro.htm |
| 2026-04-28 | ARS | cntx10-kdec312025.pdf |
| 2026-04-17 | PRE 14A | cntx-20260417.htm |
| 2026-04-02 | 8-K | cntx-20260402.htm |
| 2026-03-23 | S-8 | cntxs-82026.htm |
| 2026-03-13 | 8-K | cntx-20260311.htm |
| 2026-02-27 | 8-K | cntx-20260224.htm |
| 2026-01-08 | 8-K | cntx-20260108.htm |